IMREPLYS

This brand name is authorized in Austria, Estonia, Lithuania.

Active ingredients

The drug IMREPLYS contains one active pharmaceutical ingredient (API):

1	Sargramostim UNII 5TAA004E22 - SARGRAMOSTIM
	Sargramostim is a recombinant human GM-CSF. The binding to GM-CSF receptors expressed on the surface of target cells (haematopoietic progenitors and mature immune cells), initiates an intracellular signalling cascade which induces the cellular responses (i.e., division, maturation, activation). GM-CSF is a multilineage factor and, in addition to dose-dependent effects on the myelomonocytic lineage, it can promote the proliferation and maturation of megakaryocytic and erythroid progenitors.
	Read more about Sargramostim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMREPLYS Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA09	Sargramostim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3129229
LT	Valstybinė vaistų kontrolės tarnyba	1104728